Adenocarcinoma in Situ
Welcome,         Profile    Billing    Logout  
 4 Companies   3 Products   3 Products   0 Mechanisms of Action   2 Trials   17 News 
  • ||||||||||  Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
    Trial completion:  V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) (clinicaltrials.gov) -  Sep 20, 2016   
    P4,  N=1030, Completed, 
    Trial completion date: Apr 2018 --> May 2019 | Trial primary completion date: Apr 2018 --> Mar 2019 Active, not recruiting --> Completed
  • ||||||||||  Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
    Trial primary completion date:  V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) (clinicaltrials.gov) -  Feb 17, 2016   
    P4,  N=1000, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Aug 2016
  • ||||||||||  Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
    Enrollment closed:  V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) (clinicaltrials.gov) -  May 23, 2012   
    P4,  N=1000, Active, not recruiting, 
    Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting